{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:51:03Z","timestamp":1780494663673,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Ethics"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In the pandemic time, many low- and middle-income countries are experiencing restricted access to COVID-19 vaccines. Access to imported vaccines or ways to produce them locally became the principal source of hope for these countries. But developing a strategy for success in obtaining and allocating vaccines was not easy task. The governments in those countries have faced the difficult decision whether to accept or reject offers of vaccine diplomacy, weighing the price and availability of COVID-19 vaccines against the concerns over their efficacy and safety. We aimed to analyze public opinion regarding the governmental strategies to obtain COVID-19 vaccines in three Central Asian countries, focusing particularly on possible ethical issues.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched for opinions expressed either in Russian or in the respective national languages. We provided data on the debate within three countries, drawn from social media postings and other sources. The opinion data was not restricted by source and time. This allowed collecting a wide range of possible opinions that could be expressed regarding COVID-19 vaccine supply and human participation in the vaccine trial. We recognized ethical issues and possible questions concerning different ethical frameworks. We also considered scientific data and other information, in the process of reasoning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>As a result, public views on their respective government policies on COVID-19 vaccine supply ranged from strongly negative to slightly positive. We extracted the most important issues from public debates, for our analysis. The first issue involved trade-offs between quantity, speed, price, freedom, efficacy, and safety in the vaccines. The second set of issues arose in connection with the request to site a randomized trial in one of the countries (Uzbekistan). After considering additional evidence, we weighed individual and public risks against the benefits to make specific judgements concerning every issue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We believe that our analysis would be a helpful example of solving ethical issues that can arise concerning COVID-19 vaccine supply around the world. The public view can be highly critical, helping to spot such issues. An ignoring this view can lead to major problems, which in turn, can become a serious obstacle for the vaccine coverage and epidemics\u2019 control in the countries and regions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12910-022-00764-1","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T12:17:33Z","timestamp":1646828253000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Social network-based ethical analysis of COVID-19 vaccine supply policy in three Central Asian countries"],"prefix":"10.1186","volume":"23","author":[{"given":"Timur","family":"Aripov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wikler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damin","family":"Asadov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangir","family":"Tulekov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Totugul","family":"Murzabekova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerim M.","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"764_CR1","unstructured":"WHO. Global equitable access to COVID-19 vaccines estimated to generate economic benefits of at least US$ 153 billion in 2020\u20132021, and US$ 466 billion by 2025, in 10 major economies, according to new report by the Eurasia Group. 3 Dec 2020. https:\/\/www.who.int\/news\/item\/03-12-2020-global-access-to-covid-19-vaccines-estimated-to-generate-economic-benefits-of-at-least-153-billion-in-2020-21. Accessed 3 Mar 2021."},{"key":"764_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4750","volume":"371","author":"AD So","year":"2020","unstructured":"So AD, Woo J. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis. BMJ. 2020;371: m4750. https:\/\/doi.org\/10.1136\/bmj.m4750.","journal-title":"BMJ"},{"key":"764_CR3","unstructured":"UN News. Low-income countries have received just 0.2 per cent of all COVID-19 shots given. 9 April 2021. https:\/\/news.un.org\/en\/story\/2021\/04\/1089392. Accessed 19 Oct 2021."},{"key":"764_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4853","volume":"372","author":"L Herzog","year":"2021","unstructured":"Herzog L, Norheim O, Emanuel E, et al. Covax must go beyond proportional allocation of covid vaccines to ensure fair and equitable access. BMJ. 2021;372: m4853. https:\/\/doi.org\/10.1136\/bmj.m4853.","journal-title":"BMJ"},{"key":"764_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2020-107152","author":"S Sharma","year":"2021","unstructured":"Sharma S, Kawa N, Gomber. A WHO\u2019s allocation framework for COVAX: is it fair? J Med Ethics. 2021. https:\/\/doi.org\/10.1136\/medethics-2020-107152.","journal-title":"J Med Ethics"},{"issue":"10278","key":"764_CR6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(21)00306-8","volume":"397","author":"OJ Wouters","year":"2021","unstructured":"Wouters OJ, Shadlen KC, Salcher-Konrad M, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021;397(10278):1023\u201334. https:\/\/doi.org\/10.1016\/S0140-6736(21)00306-8.","journal-title":"Lancet"},{"key":"764_CR7","unstructured":"Morris L, Rauhala E, Mahtani S, Dixon R. China and Russia are using coronavirus vaccines to expand their influence. The U.S. is on the sidelines. The Washington Post. 24 Nov 2020. https:\/\/www.washingtonpost.com\/world\/vaccine-russia-china-influence\/2020\/11\/23\/b93daaca-25e5-11eb-9c4a-0dc6242c4814_story.html. Accessed 16 July 2021."},{"key":"764_CR8","unstructured":"Kramer AE. A Russian vaccine maker reports positive results based on an incomplete trial. The New York Times. 24 Nov 2020. https:\/\/www.nytimes.com\/2020\/11\/24\/world\/sputnik-vaccine-russia.html. Accessed 16 July 2021."},{"issue":"2","key":"764_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11019-011-9321-4","volume":"15","author":"S Schicktanz","year":"2012","unstructured":"Schicktanz S, Schweda M, Wynne B. The ethics of \u201cpublic understanding of ethics\u2019\u2013why and how bioethics expertise should include public and patients\u201d voices. Med Health Care Philos. 2012;15(2):129\u201339. https:\/\/doi.org\/10.1007\/s11019-011-9321-4.","journal-title":"Med Health Care Philos"},{"key":"764_CR10","unstructured":"BBC News. India coronavirus: Can all adults get vaccinated in 2021? 2 June 2021. https:\/\/www.bbc.com\/news\/world-asia-india-55571793. Accessed 16 July 2021."},{"key":"764_CR11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2034577.","journal-title":"N Engl J Med"},{"key":"764_CR12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.eswa.2017.02.006","volume":"78","author":"REL Condori","year":"2017","unstructured":"Condori REL, Pardo TAS. Opinion summarization methods: comparing and extending extractive and abstractive approaches. Expert Syst Appl. 2017;78:124\u201334. https:\/\/doi.org\/10.1016\/j.eswa.2017.02.006.","journal-title":"Expert Syst Appl"},{"key":"764_CR13","unstructured":"Bonde S and Firenze P. Making Choices: A Framework for Making Ethical Decisions. Brown University. 2013. https:\/\/www.brown.edu\/academics\/science-and-technology-studies\/framework-making-ethical-decisions. Accessed 16 July 2021."},{"key":"764_CR14","unstructured":"Paul R and Elder L. The Miniature Guide to Understanding the Foundations of Ethical Reasoning. The Foundation for Critical Thinking. 2003"},{"key":"764_CR15","unstructured":"United Nations. Universal Declaration of Human Rights. December 10, 1948. https:\/\/www.un.org\/en\/universal-declaration-human-rights\/. Accessed 16 July 2021."},{"key":"764_CR16","unstructured":"International Ethical Guidelines for Health-related Research Involving Humans. Prepared by the Council for International Organizations of Medical Sciences (CIOMS) in collaboration with the World Health Organization (WHO). 2016, Geneva. https:\/\/cioms.ch\/wp-content\/uploads\/2017\/01\/WEB-CIOMS-EthicalGuidelines.pdf. Accessed 16 July 2021."},{"issue":"10263","key":"764_CR17","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/S0140-6736(20)32318-7","volume":"396","author":"RM Anderson","year":"2020","unstructured":"Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Lancet. 2020;396(10263):1614\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(20)32318-7.","journal-title":"Lancet"},{"key":"764_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1605","volume":"373","author":"C Baraniuk","year":"2021","unstructured":"Baraniuk C. How long does covid-19 immunity last? BMJ. 2021;373: n1605. https:\/\/doi.org\/10.1136\/bmj.n1605.","journal-title":"BMJ"},{"key":"764_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n579","volume":"372","author":"R Challen","year":"2021","unstructured":"Challen R, Brooks-Pollock E, Read JM, et al. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012\/1: matched cohort study. BMJ. 2021;372: n579. https:\/\/doi.org\/10.1136\/bmj.n579.","journal-title":"BMJ"},{"key":"764_CR20","unstructured":"The Economist. Delta is fast becoming the world\u2019s dominant strain of SARS-CoV-2. 29 June 2021. https:\/\/www.economist.com\/graphic-detail\/2021\/06\/29\/delta-is-fast-becoming-the-worlds-dominant-strain-of-sars-cov-2. Accessed 16 July 2021."},{"key":"764_CR21","unstructured":"BBC News. Covid: US reports record infections as Europe's Omicron cases also soar. 29 December 2021. https:\/\/www.bbc.com\/news\/world-59814661. Accessed 2 Jan 2022."},{"key":"764_CR22","unstructured":"WHO. COVID-19 vaccine tracker and landscape. 4 January 2022. https:\/\/cdn.who.int\/media\/docs\/default-source\/blue-print\/04.01.2022_novel-covid-19-vaccine-tracker.xlsx.zip?sfvrsn=6e4cce63_7&download=true. Accessed 5 Jan 2022."},{"key":"764_CR23","unstructured":"WHO. Status of COVID-19 Vaccines within WHO EUL\/PQ evaluation process. 23 December 2021. https:\/\/extranet.who.int\/pqweb\/key-resources\/documents\/status-covid-19-vaccines-within-who-eulpq-evaluation-process. Accessed 5 Jan 2022."},{"issue":"10275","key":"764_CR24","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"DY Logunov","year":"2021","unstructured":"Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase III trial in Russia. Lancet. 2021;397(10275):671\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(21)00234-8.","journal-title":"Lancet"},{"key":"764_CR25","unstructured":"BBC News. Sinopharm: Chinese Covid vaccine gets WHO emergency approval. 7 May 2021. https:\/\/www.bbc.com\/news\/world-asia-china-56967973. Accessed 16 July 2021."},{"key":"764_CR26","unstructured":"BBC News. Covid: China's Sinovac vaccine gets WHO emergency approval. 2 June 2021. https:\/\/www.bbc.com\/news\/world-asia-china-57322504. Accessed 23 Oct 2021."},{"issue":"4","key":"764_CR27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.amepre.2020.06.011","volume":"59","author":"SM Bartsch","year":"2020","unstructured":"Bartsch SM, O\u2019Shea KJ, Ferguson MC, et al. Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention. Am J Prev Med. 2020;59(4):493\u2013503. https:\/\/doi.org\/10.1016\/j.amepre.2020.06.011.","journal-title":"Am J Prev Med"},{"issue":"10269","key":"764_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99\u2013111. https:\/\/doi.org\/10.1016\/S0140-6736(20)32661-1.","journal-title":"Lancet"},{"key":"764_CR29","unstructured":"BBC News. Covid: What do we know about China's coronavirus vaccines? 14 Jan 2021. https:\/\/www.bbc.com\/news\/world-asia-china-55212787. Accessed 16 July 2021."},{"key":"764_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2020-106850","author":"R Gupta","year":"2020","unstructured":"Gupta R, Morain SR. Ethical allocation of future COVID-19 vaccines. J Med Ethics. 2020. https:\/\/doi.org\/10.1136\/medethics-2020-106850.","journal-title":"J Med Ethics"},{"issue":"2","key":"764_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2020-004812","volume":"6","author":"A Herlitz","year":"2021","unstructured":"Herlitz A, Lederman Z, Miller J, et al. Just allocation of COVID-19 vaccines. BMJ Glob Health. 2021;6(2): e004812. https:\/\/doi.org\/10.1136\/bmjgh-2020-004812.","journal-title":"BMJ Glob Health"},{"issue":"2","key":"764_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/medethics-2020-106821","volume":"47","author":"J Savulescu","year":"2021","unstructured":"Savulescu J. Good reasons to vaccinate: mandatory or payment for risk? J Med Ethics. 2021;47(2):78\u201385. https:\/\/doi.org\/10.1136\/medethics-2020-106821.","journal-title":"J Med Ethics"},{"key":"764_CR33","unstructured":"Institute for Health Metrics and Evaluation (IHME). Estimation of total mortality due to COVID-19. http:\/\/www.healthdata.org\/special-analysis\/estimation-excess-mortality-due-covid-19-and-scalars-reported-covid-19-deaths. Accessed 16 July 2021."},{"issue":"7","key":"764_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(20)30177-4","volume":"1","author":"VS Balakrishnan","year":"2020","unstructured":"Balakrishnan VS. COVID-19 response in Central Asia. Lancet Microbe. 2020;1(7): e281. https:\/\/doi.org\/10.1016\/S2666-5247(20)30177-4.","journal-title":"Lancet Microbe"},{"issue":"10242","key":"764_CR35","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/S0140-6736(20)31142-9","volume":"395","author":"DK Chu","year":"2020","unstructured":"Chu DK, Akl EA, Duda S, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395(10242):1973\u201387. https:\/\/doi.org\/10.1016\/S0140-6736(20)31142-9.","journal-title":"Lancet"},{"issue":"12","key":"764_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243262","volume":"15","author":"D Bertsimas","year":"2020","unstructured":"Bertsimas D, Lukin G, Mingardi L, et al. COVID-19 mortality risk assessment: an international multi-center study. PLoS ONE. 2020;15(12): e0243262. https:\/\/doi.org\/10.1371\/journal.pone.0243262.","journal-title":"PLoS ONE"},{"issue":"12","key":"764_CR37","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1080\/21645515.2020.1820808","volume":"16","author":"T Yadav","year":"2020","unstructured":"Yadav T, Srivastava N, Mishra G, et al. Recombinant vaccines for COVID-19. Hum Vaccin Immunother. 2020;16(12):2905\u201312. https:\/\/doi.org\/10.1080\/21645515.2020.1820808.","journal-title":"Hum Vaccin Immunother"}],"container-title":["BMC Medical Ethics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12910-022-00764-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12910-022-00764-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12910-022-00764-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T12:18:28Z","timestamp":1646828308000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedethics.biomedcentral.com\/articles\/10.1186\/s12910-022-00764-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["764"],"URL":"https:\/\/doi.org\/10.1186\/s12910-022-00764-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-745691\/v1","asserted-by":"object"}]},"ISSN":["1472-6939"],"issn-type":[{"value":"1472-6939","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]},"assertion":[{"value":"24 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Committee of Bioethics at Medical Association of Uzbekistan (No. 86, from Nov. 23, 2020). The subjects of the study did not provide their formal agreement to participate in the study.\u00a0We analyzed\u00a0only publicly available information from Internet.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}